

# Savina Sn Nodari

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5578254/savina-sn-nodari-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106  
papers

5,305  
citations

33  
h-index

72  
g-index

140  
ext. papers

6,313  
ext. citations

4.2  
avg, IF

5.3  
L-index

#	Paper	IF	Citations
106	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1123-1133	15.1	1160
105	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. <i>European Heart Journal</i> , <b>2020</b> , 41, 2083-2088	9.5	437
104	Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. <i>European Heart Journal</i> , <b>2020</b> , 41, 1821-1829	9.5	299
103	Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 188-95	12.3	285
102	Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. <i>Circulation</i> , <b>2000</b> , 102, 546-51	16.7	282
101	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 97-112	7.9	213
100	Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 1248-58	15.1	179
99	Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 870-9	15.1	153
98	Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 194-202	12.3	126
97	The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 776-86	12.3	122
96	Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 1805-11	15.1	122
95	Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1401-11	12.3	100
94	Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 33, 943-50	15.1	100
93	Off-pump coronary artery bypass surgery technique for total arterial myocardial revascularization: a prospective randomized study. <i>Annals of Thoracic Surgery</i> , <b>2003</b> , 76, 778-82; discussion 783	2.7	99
92	Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. <i>European Journal of Heart Failure</i> , <b>2003</b> , 5, 621-7	12.3	98
91	n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. <i>Circulation</i> , <b>2011</b> , 124, 1100-6	16.7	94
90	Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. <i>American Heart Journal</i> , <b>2003</b> , 145, 292-9	4.9	94

89	Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. <i>International Journal of Cardiology</i> , <b>2013</b> , 163, 206-11	3.2	85
88	The 6-min walking test early after cardiac surgery. Reference values and the effects of rehabilitation programme. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2007</b> , 32, 724-9	3	76
87	Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 750-8	7.6	62
86	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 54-65	12.3	57
85	A rationale for the use of beta-blockers as standard treatment for heart failure. <i>American Heart Journal</i> , <b>2000</b> , 139, 511-21	4.9	53
84	Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. <i>Nutrition</i> , <b>2015</b> , 31, 72-8	4.8	47
83	The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. <i>Cardiovascular Drugs and Therapy</i> , <b>2009</b> , 23, 5-15	3.9	47
82	Mediterranean diet impact on cardiovascular diseases: a narrative review. <i>Journal of Cardiovascular Medicine</i> , <b>2017</b> , 18, 925-935	1.9	46
81	Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. <i>Journal of Cardiovascular Medicine</i> , <b>2011</b> , 12, 76-84	1.9	45
80	Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 574-81	3	40
79	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , <b>2014</b> , 19, 135-52	5	39
78	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , <b>2013</b> , 18, 107-22	5	39
77	Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery. <i>Circulation</i> , <b>2003</b> , 108 Suppl 1, II29-33	16.7	35
76	Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. <i>Clinical Medicine Insights: Cardiology</i> , <b>2014</b> , 8, 39-44	3.2	34
75	Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. <i>European Heart Journal</i> , <b>2004</b> , 25, 1534-41	9.5	34
74	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , <b>2017</b> , 57, 440-451	2.9	33
73	Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. <i>Annals of Hematology</i> , <b>2017</b> , 96, 549-558	3	32
72	Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1231-5	3	28

71	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 790-6 <sup>3</sup>		28
70	Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 401-8	7.6	27
69	Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. <i>European Journal of Heart Failure</i> , <b>2006</b> , 8, 131-5	12.3	26
68	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 429-437	3.3	19
67	CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. <i>Echocardiography</i> , <b>2008</b> , 25, 955-60	1.5	19
66	Preventing antineoplastic drug-related cardiomyopathy: old and new therapeutic strategies. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17 Suppl 1, S64-75	1.9	18
65	Is total arterial myocardial revascularization with composite grafts a safe and useful procedure in the elderly?. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2003</b> , 23, 657-64; discussion 664	3	18
64	Redefining biomarkers in heart failure. <i>Heart Failure Reviews</i> , <b>2018</b> , 23, 237-253	5	17
63	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 281-291	12.3	17
62	Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. <i>American Journal of the Medical Sciences</i> , <b>2014</b> , 347, 271-6	2.2	17
61	Prevention and management of chronic heart failure in patients at risk. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 10F-17F	3	17
60	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 71, 23-31	3.9	17
59	Role of biomarkers in monitoring antineoplastic cardiotoxicity. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17 Suppl 1, S27-34	1.9	17
58	Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. <i>European Journal of Heart Failure</i> , <b>2003</b> , 5, 803-9 <sup>12.3</sup>		15
57	Beta-blockade in heart failure: selective versus nonselective agents. <i>American Journal of Cardiovascular Drugs</i> , <b>2001</b> , 1, 3-14	4	14
56	High sensitivity C-reactive protein: a predictor for recurrence of atrial fibrillation after successful cardioversion. <i>Internal and Emergency Medicine</i> , <b>2009</b> , 4, 309-13	3.7	13
55	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 340-6	3	12
54	Six-year prognosis of diabetic patients with coronary artery disease. <i>European Journal of Clinical Investigation</i> , <b>2012</b> , 42, 376-83	4.6	12

53	Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?. <i>Current Heart Failure Reports</i> , <b>2010</b> , 7, 100-9	2.8	12
52	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , <b>2015</b> , 13, 799-809	2.5	10
51	Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial. <i>Clinical Pharmacology in Drug Development</i> , <b>2019</b> , 8, 942-951	2.3	10
50	Effects of supplementation with polyunsaturated fatty acids in patients with heart failure. <i>Internal and Emergency Medicine</i> , <b>2011</b> , 6 Suppl 1, 37-44	3.7	9
49	Current treatment in acute and chronic cardio-renal syndrome. <i>Heart Failure Reviews</i> , <b>2011</b> , 16, 583-94	5	8
48	Persistence of left superior vena cava, absence of coronary sinus and cerebral ictus. <i>International Journal of Cardiology</i> , <b>2008</b> , 126, e39-41	3.2	8
47	Lack of association of coeliac disease with idiopathic and ischaemic dilated cardiomyopathies. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2008</b> , 68, 692-5	2	8
46	Management of heart failure in the new era: the role of scores. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17, 569-80	1.9	8
45	Nitric oxide and cardiovascular risk factors. <i>Heart International</i> , <b>2007</b> , 3, 18	0.3	7
44	A new educational program in heart failure drug development: the Brescia international master program. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19, 411-421	1.9	7
43	Clinical impact of renal dysfunction in heart failure. <i>Reviews in Cardiovascular Medicine</i> , <b>2011</b> , 12, 186-99	3.9	7
42	Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2013</b> , 112, 1763-9	3	6
41	Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , <b>2012</b> , 5, 718	0.8	6
40	Vericiguat for Heart Failure with Reduced Ejection Fraction. <i>Current Cardiology Reports</i> , <b>2021</b> , 23, 144	4.2	6
39	Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report. <i>Journal of Cardiovascular Medicine</i> , <b>2006</b> , 7, 182-7	1.9	5
38	Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. <i>Therapeutics and Clinical Risk Management</i> , <b>2007</b> , 3, 569-78	2.9	5
37	An expression of concern on research during the Covid-19 pandemic. <i>Journal of Cardiovascular Medicine</i> , <b>2020</b> , 21, 838-839	1.9	5
36	Impact of 2020 SARS-CoV-2 outbreak on telemedicine management of cardiovascular disease in Italy. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 1191-1196	3.7	4

35	Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial. <i>American Heart Journal</i> , <b>2020</b> , 224, 129-137	4.9	4
34	The left ventricle as a mechanical engine: from Leonardo da Vinci to the echocardiographic assessment of peak power output-to-left ventricular mass. <i>Journal of Cardiovascular Medicine</i> , <b>2013</b> , 14, 214-20	1.9	4
33	Acute heart failure syndromes: assessment and reconstructing the heart. <i>Journal of Cardiovascular Medicine</i> , <b>2011</b> , 12, 258-63	1.9	4
32	Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients. <i>International Journal of Nephrology and Renovascular Disease</i> , <b>2010</b> , 3, 51-60	2.5	4
31	Maximal and Submaximal Exercise Testing in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , <b>1998</b> , 32, S36-S45	3.1	4
30	Right heart dysfunction: from pathophysiologic insights to therapeutic options: a translational overview. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19, 613-623	1.9	4
29	The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia. <i>Heart International</i> , <b>2007</b> , 3, 12	0.3	3
28	Beta-blocker therapy of heart failure: an update. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 289-98	4	2
27	Non-compaction of the ventricular myocardium. <i>Heart International</i> , <b>2006</b> , 2, 178	0.3	2
26	Current guidelines in the pharmacological management of chronic heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2004</b> , 5 Suppl 1, S11-6	3	2
25	Beta Blockers in Heart Failure: Issues in Management of Individual Patients. <i>Heart Failure Reviews</i> , <b>1999</b> , 4, 65-78	5	2
24	Pharmacological activity of the new calcium antagonist, lacidipine, on isolated preparations. <i>General Pharmacology</i> , <b>1996</b> , 27, 1255-9		2
23	Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization. <i>Heart International</i> , <b>2006</b> , 2, 136	0.3	2
22	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	2
21	The oldest Society of Cardiology in Italy meets the ESC. <i>European Heart Journal</i> , <b>2020</b> , 41, 2055-2058	9.5	1
20	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. <i>Heart Failure Reviews</i> , <b>2020</b> , 1	5	1
19	Questioning the Associations of EB Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 781	16.2	1
18	Improved Graft Patency Rates and Mid-Term Outcome of Diabetic Patients Undergoing Total Arterial Myocardial Revascularization. <i>Heart International</i> , <b>2006</b> , 2, 182618680600200	0.3	1

17	Selective or nonselective beta-adrenergic blockade in patients with congestive heart failure. <i>Current Cardiology Reports</i> , <b>2000</b> , 2, 252-7	4.2	1
16	Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan.. <i>ESC Heart Failure</i> , <b>2022</b> ,	3.7	1
15	Genetic test for Mendelian fatigue and muscle weakness syndromes. <i>Acta Biomedica</i> , <b>2020</b> , 91, e20200013.2	1.2	1
14	Endothelial damage due to air pollution. <i>Heart International</i> , <b>2006</b> , 2, 115	0.3	1
13	The study of left ventricular diastolic function by Doppler echocardiography: the essential for the clinician. <i>Heart International</i> , <b>2007</b> , 3, 42	0.3	1
12	Effects of the COVID-19 pandemic on the formation of fellows in training in cardiology. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 22, 711-715	1.9	1
11	New Targets in Heart Failure Drug Therapy. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 665797	5.4	1
10	Comprehensive heart failure assessment: A challenge to modify the course of heart failure. Author's reply. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 74, 125-126	3.9	0
9	Quick response code applications in medical and cardiology settings: a systematic scoping review. <i>European Heart Journal Digital Health</i> , <b>2021</b> , 2, 336-341	2.3	0
8	Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article "The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy" <i>Cardiovascular Drugs and Therapy</i> , <b>2009</b> , 23, 335-336	3.9	
7	Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction1-30		
6	Endothelial Damage Due to Air Pollution. <i>Heart International</i> , <b>2006</b> , 2, 182618680600200	0.3	
5	Managing heart failure in the very old. <i>Aging Health</i> , <b>2006</b> , 2, 253-275		
4	Combined invasive and noninvasive study of left ventricular systolic and diastolic function following acute administration of cicloprolol to subjects with normal cardiac function. <i>Cardiovascular Drugs and Therapy</i> , <b>1992</b> , 6, 513-7	3.9	
3	The Prevention of Sudden Death: New Perspectives <b>2007</b> , 205-213		
2	Endocannabinoids and cardiovascular prevention: real progress?. <i>Heart International</i> , <b>2007</b> , 3, 27	0.3	
1	Anemia and heart failure: a cause of progression or only a consequence?. <i>Heart International</i> , <b>2007</b> , 3, 1	0.3	